Furthermore, in some BCP-ALL cases with unfavorable karyotypes, such as dic(9;20), KMT2A-rearranged, and hypodiploidy, determining the methylation status of the DR4 and DR5 genes could be clinically useful in predicting immunotherapy success [186]. This evidence concerns the gene TNFRSF10A and acute lymphoblastic leukemia.